Heroin Dependence Clinical Trial
Official title:
A Novel Methadone-induced Memory Retrieval-extinction Procedure to Prevent Heroin Craving and Relapse
Verified date | October 2019 |
Source | National Institute on Drug Dependence, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study assessed the efficacy of a methadone-induced memory retrieval-extinction procedure on heroin craving and relapse. Male participants aged 18-55 years old and prescribed MMT to treat heroin dependence were included in the present study, and randomly assigned to receive methadone, or receive methadone plus 10 minutes plus extinction, or receive methadone plus 6 hours plus extinction. The intervention persisted 3 times per week for 4 weeks. Then the subjects were followed up once a month for cue induced heroin craving and relapse.
Status | Completed |
Enrollment | 87 |
Est. completion date | April 20, 2019 |
Est. primary completion date | April 23, 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - met the diagnostic criteria of heroin dependence according to DSM-IV - were prescribed methadone maintenance treatment (MMT) and took it regularly - no change in city of residence for at least 1 year - had normal blood pressure and heart rate - had negative urine morphine screening test - primary-school level education - provide signed consent Exclusion Criteria: - other substance abuse(except nicotine) - had a current or past history of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition(DSM-IV) Axis?disorders - had clinically evident physical disorders - neurological signs and/or history of neurological disease - noncompliance with the procedure |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Dependence, China |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of cue induced heroin craving | Heroin craving will be assessed using a visual analog scale (VAS), i.e., an undivided line marked at the left and right ends with 0 ("not at all") and 10 ("extremely high"). | Baseline (Day 0 ), post-intervention (1 month), monthly during follow-up for 4 months (2, 3, 4 and 5 month) | |
Primary | change of negative urinary morphine test | All the participants will be required to have urine tests for morphine during screening, weekly during intervention and monthly during follow-up. | Baseline (Day 0), weekly during intervention(1, 2, 3 and 4 week) and monthly during follow-up for 4 months (2, 3, 4 and 5 month) | |
Secondary | cue induced heart rate change | Heart rate will be monitored immediately before and after cue exposure | Baseline (Day 0 ), post-intervention (1 month), monthly during follow-up for 4 months (2, 3, 4 and 5 month) | |
Secondary | cue induced blood pressure change | Blood pressure will be monitored immediately before and after cue exposure. | Baseline (Day 0 ), post-intervention (1 month), monthly during follow-up for 4 months (2, 3, 4 and 5 month) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Completed |
NCT00000210 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
|
Phase 2 | |
Completed |
NCT00000211 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
|
Phase 2 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Withdrawn |
NCT00000330 -
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
|
Phase 2 | |
Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
Completed |
NCT00218127 -
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
|
Phase 2 | |
Completed |
NCT00015288 -
Buprenorphine and Naloxone Combination Study - 10
|
Phase 1 | |
Terminated |
NCT03711318 -
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
|
Phase 3 | |
Recruiting |
NCT02541526 -
Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
|
Phase 3 | |
Active, not recruiting |
NCT02541513 -
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
|
Phase 3 | |
Completed |
NCT01760473 -
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
|
Phase 3 | |
Terminated |
NCT01395797 -
Pioglitazone for Heroin and for Nicotine Dependence
|
Phase 1/Phase 2 | |
Completed |
NCT01668706 -
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
|
N/A | |
Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 | |
Completed |
NCT00684840 -
Effects of Stress and Other Factors on Opiate Drug Choice.
|
N/A | |
Completed |
NCT00759005 -
Effect of Stress on Heroin-Related Memory Retrieval
|
N/A | |
Completed |
NCT00218530 -
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
|
Phase 1 | |
Completed |
NCT00158288 -
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
|
Phase 2 |